Redeye: Remedy - Lowered budget assumptions on key projects
Redeye keeps its valuation range and base case unchanged despite a lowered revenue and EBIT expectation in 2023. Since decreased budget assumptions only have an impact on Remedy’s short-term revenue, we are still optimistic regarding its more long-term prospects, due to the fact that a lower budget in our view increases the royalty opportunity.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/